8-K: Exact Sciences Reports Record Q4, Full-Year 2025 Results

Exact Sciences Corporation announced record fourth quarter and full year 2025 financial results, driven by strong growth in Screening and Precision Oncology revenue, alongside significant advancements in its cancer diagnostic pipeline and progress towards its merger with Abbott Laboratories.

Summary

• Total fourth quarter 2025 revenue was $878 million, an increase of 23% on a reported and core revenue basis.
• Screening revenue for Q4 2025 was $695 million, an increase of 26%.
• Precision Oncology revenue for Q4 2025 was $183 million, an increase of 14% (16% on a core revenue basis).
• Total full year 2025 revenue reached $3.25 billion, an increase of 18% on a reported and core revenue basis.
• Full year 2025 Screening revenue was $2.53 billion, and Precision Oncology revenue was $717 million.
• Operating cash flow for the full year 2025 was $491 million, an improvement of 133%.
• Free cash flow for the full year 2025 was $357 million, an improvement of 379%.
• Net loss for the full year 2025 was $208 million, an improvement of $821 million compared to 2024.
• Adjusted EBITDA for the full year 2025 was $400 million, an improvement of $77 million compared to 2024.
• Announced first clinical study results for the Oncodetect molecular residual disease test in breast cancer, showing strong prediction of distant recurrence in early triple-negative breast cancer.
• Announced pivotal clinical validation results from the ALTUS study, demonstrating the Oncoguard Liver blood test's superior early-stage and overall sensitivity for hepatocellular carcinoma compared to the current standard of care.
• The Hart-Scott-Rodino waiting period expired for the exclusive license agreement with Freenome Holdings, Inc., granting U.S. rights to Freenome's blood-based colorectal cancer screening tests.
• The pending merger with Abbott Laboratories is progressing, with a special meeting of stockholders scheduled for February 20, 2026, and an expected closing in the second quarter of 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a very positive report, highlighting strong financial performance, significant pipeline advancements, and strategic progress towards the Abbott merger, all of which enhance the company's market position and future prospects.

Positives

• Achieved record fourth quarter and full year 2025 revenue, demonstrating strong top-line growth.
• Total revenue increased by 23% in Q4 2025 and 18% for the full year 2025 on both reported and core revenue bases.
• Screening revenue showed robust growth, increasing by 26% in Q4 2025.
• Significant improvement in full-year 2025 operating cash flow, up 133% to $491 million.
• Substantial increase in full-year 2025 free cash flow, up 379% to $357 million.
• Net loss for full-year 2025 improved by $821 million, indicating progress towards profitability.
• Adjusted EBITDA for full-year 2025 increased by $77 million to $400 million.
• Successfully launched three new tests in 2025, expanding the product portfolio.
• Positive clinical study results for the Oncodetect test in triple-negative breast cancer, a difficult-to-treat subtype.
• Pivotal clinical validation results for the Oncoguard Liver blood test demonstrated superior sensitivity for liver cancer compared to the standard of care.
• Secured exclusive U.S. rights to Freenome's blood-based colorectal cancer screening tests, expanding leadership in cancer screening.
• Progress towards the merger with Abbott Laboratories, expected to close in Q2 2026, which could enhance market reach and resources.

Negatives

• Net loss for Q4 2025 was $86 million, or $0.45 per share, an increase from a net loss of $49.8 million, or $0.27 per share, in Q4 2024.
• Adjusted EBITDA for Q4 2025 was $63 million, down from $75.381 million in Q4 2024, impacted by a $75.0 million R&D expense related to the Freenome collaboration and license agreement.
• The company will not be holding a fourth quarter conference call due to the pending merger, which may limit immediate investor engagement.

Risks

• Ability to successfully develop and commercialize new products and services and assess potential market opportunities.
• Ability to successfully and profitably market products and services.
• Acceptance of products and services by patients and healthcare providers.
• Reliance upon certain suppliers.
• Ability to retain and hire key personnel.
• Approval and maintenance of adequate reimbursement rates for products and services within and outside of the U.S.
• Amount and nature of competition for products and services.
• Effects of any judicial, executive or legislative action affecting the company or the healthcare system.
• Changes in government policies, laws, regulations, and staffing.
• Recommendations, guidelines and quality metrics issued by various organizations regarding cancer screening or products and services.
• Ability to obtain and maintain regulatory approvals and comply with applicable regulations.
• Ability to protect and enforce intellectual property.
• Success establishing and maintaining collaborative, licensing, and supplier arrangements.
• Results of validation studies and clinical trials, including the risks that the results of future studies and trials may differ materially from the results of previously completed studies and trials.
• Ability to manage an international business and expectations regarding international expansion and opportunities.
• Potential effects of changing macroeconomic conditions and geopolitical conflict.
• Possibility that the anticipated benefits from business acquisitions will not be realized in full or at all or may take longer to realize than expected.
• Outcome of any potential litigation or legal proceeding.
• Ability to raise the capital necessary to support operations or meet payment obligations under indebtedness.
• Risks and uncertainties related to the proposed acquisition by Abbott Laboratories, including the possible inability of the parties to consummate the proposed transaction on a timely basis or at all.
• Possible inability of the parties to satisfy the conditions precedent to consummation of the proposed transaction, including necessary regulatory approvals and the requisite vote by stockholders, on a timely basis or at all.
• Possible occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement relating to the proposed transaction.
• Risk that the merger agreement may be terminated in circumstances that require the company to pay a termination fee.
• Possibility that competing offers to acquire the company may be made.
• Potential adverse impact on the company of contractual restrictions under the merger agreement that limit the ability to pursue business opportunities or strategic transactions.
• Risks relating to significant transaction costs associated with the proposed transaction and the possibility that the proposed transaction may be more expensive to complete than anticipated.
• Potential adverse effects of the announcement or pendency of the proposed transaction, or any failure to complete the proposed transaction, on the market price of common stock or on the ability to develop and maintain relationships with personnel and customers, suppliers and others with whom business is done or otherwise on business, financial condition, results of operations and financial performance.
• Risks related to diversion of management's attention from ongoing business operations due to the proposed transaction.
• Risk of litigation and/or regulatory actions related to the proposed transaction or business and the outcome of any such litigation or regulatory action.

Future Outlook

Momentum continues to build with core products driving strong growth and an expanding portfolio. The company is uniquely positioned to drive lasting change in cancer detection and treatment globally. The merger with Abbott Laboratories is expected to close in the second quarter of 2026, subject to regulatory approvals and customary closing conditions.

Management Comments

• "In 2025 the Exact Sciences team delivered on our mission by screening more people than ever before, helping guide more personalized treatment decisions, and successfully launching three new tests." Kevin Conroy, Chairman and CEO of Exact Sciences.
• "These defining milestones show what the Exact Sciences team can achieve through a relentless focus on our mission and a dedication to improving the lives of patients." Kevin Conroy, Chairman and CEO of Exact Sciences.
• "As we look to the future, momentum continues to build. Our core products are driving strong growth, our portfolio is expanding, and we are uniquely positioned to drive lasting change in the way cancer is found and treated globally." Kevin Conroy, Chairman and CEO of Exact Sciences.

Industry Context

StockSavvy.ai notes that Exact Sciences' strong revenue growth and pipeline advancements, particularly in multi-cancer early detection and molecular residual disease, position it favorably within the competitive diagnostics market. The pending acquisition by Abbott Laboratories underscores the strategic value of its portfolio, especially Cologuard and its emerging blood-based tests, in a rapidly evolving landscape focused on early and precise cancer intervention.

Comparison to Industry Standards

• The superior early-stage and overall sensitivity of the Oncoguard Liver blood test for hepatocellular carcinoma, compared to the current standard of care, positions it as a potential leader in liver cancer diagnostics.
• The Cologuard Plus test's expected reduction of false positives by nearly 40% sets a new benchmark for non-invasive colorectal cancer screening, aiming to minimize unnecessary follow-up colonoscopies, a key patient and healthcare system benefit.

Stakeholder Impact

• Shareholders: Potential for increased value through the pending merger with Abbott Laboratories.
• Patients: Improved access to advanced cancer screening and diagnostic tests (Cologuard Plus, Oncodetect, Oncoguard Liver, Freenome's blood-based CRC test).
• Employees: Potential integration into Abbott Laboratories, with possible changes in roles or structure.
• Healthcare Providers: Enhanced tools for early cancer detection and personalized treatment decisions.

Next Steps

• Special meeting of stockholders on February 20, 2026, to adopt the Merger Agreement with Abbott Laboratories.
• Closing of the merger with Abbott Laboratories expected in the second quarter of 2026, subject to obtaining required regulatory approvals and satisfaction or waiver of other customary closing conditions.
• Continued engagement with regulators reviewing the proposed transaction.
• Freenome's blood-based CRC screening test receiving first-line FDA approval for exclusivity to remain subject.

Key Dates

Recommendation

The company delivered record financial results with substantial revenue growth and significant improvements in cash flow and net loss. Strategic advancements in its product pipeline, including positive clinical data for new tests and the acquisition of exclusive rights to Freenome's blood-based CRC screening, position it for continued market leadership. The pending merger with Abbott Laboratories, expected to close in Q2 2026, provides a clear path to enhanced scale and market reach, making the stock a strong buy for investors seeking exposure to a growing leader in cancer diagnostics.

Keywords

Exact Sciences, EXAS, cancer screening, diagnostic tests, Cologuard, Oncotype DX, Precision Oncology, molecular residual disease, Oncodetect, Oncoguard Liver, Freenome, Abbott Laboratories merger, financial results, Q4 2025, full year 2025, revenue growth, EBITDA, cash flow, biotechnology, healthcare, medical diagnostics